Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bristol
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Bristol, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca24 Eli Lilly and Company18 Merck Sharp & Dohme LLC17 Boehringer Ingelheim10 Janssen Research & Development, LLC9
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Bristol

271 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Microbio Co Ltd
Observational
1,500
Bristol
2026-11
Not yet open
PKU Microtablets Case Studies
NCT07671859Phenylketonuria (PKU)
Nutricia UK Ltd
Not applicable
20
Bristol
2026-10-01
Recruiting
AstraZeneca
Phase 3
2,800
Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea
2026-09-01
Not yet open
HALEON
Not applicable
192
Bristol
2026-09
Recruiting
Kardigan, Inc.
Phase 3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-08-26
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Ashton-under-Lyne, Basildon, Belfast, Birmingham, Brighton, Bristol, Cardiff, Clydebank
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Newquay, Yeovil, Rotherham, Bristol, Coventry, Hull, Ipswich, Londonderry
2026-08-24
Recruiting
Boehringer Ingelheim
Phase 3
448
Bristol, Leeds, London, Salford
2026-07-27
Recruiting
AstraZeneca
Phase 3
915
Bristol, Cambridge, Preston, Sheffield
2026-07-16
Recruiting
AstraZeneca
Phase 3
1,200
Aberdeen, Addlestone, Banbury, Bristol, Edinburgh, Hounslow, Penzance, Poole
2026-07-06
Recruiting
Stealth BioTherapeutics Inc.
Phase 4
48
Bristol
2026-07-02
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bristol, Cottingham, Edinburgh, Exeter, Liverpool, London
2026-06-11
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Bristol, Liverpool, London, Nottingham
2026-06-02
Recruiting
Bayer
Phase 3
117
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2026-06-01
Recruiting
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Recruiting
Pfizer
Phase 2
24
London, Bristol, Liverpool, Sheffield
2026-05-28
Recruiting
Alfasigma S.p.A.
Phase 3
65
Bristol, Leicester, Nottingham
2026-05-21
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
Bristol, Glasgow, Liverpool, London, Manchester
2026-04-20
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Blackpool, Aberdeen, Antrim, Bristol, Dundee, Hounslow, Hull, Nuneaton
2026-03-23
Active, closed
ModernaTX, Inc.
Phase 3
4,050
Bristol, High Wycombe, Peterborough, Stockton-on-Tees, Bournemouth, Weymouth, Glasgow, Enfield
2026-03-23
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Active, closed
Pfizer
Phase 3
1,078
Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston, Enfield
2026-02-24
Recruiting
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Recruiting
Kardigan, Inc.
Phase 2/3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Recruiting
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
High Wycombe, Ashburton, Bristol, London, Romford, Rotherham, Thetford, Nottingham
2026-01-20
Recruiting
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Active, closed
Pfizer
Phase 3
3,578
Sandbach, Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston
2025-12-19
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
780
Belfast, Bristol, Dagenham, London, Maidstone, Manchester, Orpington, Portsmouth
2025-12-17
Recruiting
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
By invitation
Celldex Therapeutics
Phase 3
1,370
Leeds, Bristol, Cambridge, Glasgow, North Finchley
2025-11-25
Recruiting
Bayer
Phase 3
111
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2025-11-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Bristol, Yate, London, Corby
2025-11-11
Recruiting
AbbVie
Phase 3
561
Gloucester, London, Liverpool, Bristol, Newcastle upon Tyne, Sunderland
2025-11-05
Recruiting
BioNTech SE
Phase 3
558
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
Gesynta Pharma AB
Phase 2
190
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Bristol, Cambridge, Frimley, Hampstead, London, Plymouth
2025-10-01
Recruiting
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield
2025-09-29
Active, closed
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Aberdeen, Bristol, High Wycombe, Peterborough, Truro, Edinburgh, Birmingham, Blackpool
2025-09-25
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Ashburton, Belfast, Bellshill, Birmingham, Bristol, Bury St Edmunds, Cambridge, Cardiff
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belfast, Birmingham, Blackpool, Bodelwyddan, Bradford on Avon, Bristol, Bromborough, Enfield
2025-09-02
Recruiting
Pfizer
Phase 3
6,000
Bristol, London, Manchester, Truro, Southampton, Oxford, Shropshire, Leeds
2025-08-25
Recruiting
e-Sense® Normal Values of Urodynamic Pressures Using e-Sense® Catheters
NCT06905808Lower Urinary Track Symptoms, Urodynamic Exam
Laborie Medical Technologies Inc.
Observational
40
Bristol
2025-08-15
Recruiting
GlaxoSmithKline
Phase 2
220
Birmingham, Bristol, London
2025-08-14
Recruiting
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
Amgen
Phase 3
12,800
Birmingham, Blackpool, Bristol, Cambridge, Chester, Coventry, Dudley, Dundee
2025-07-25
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Birmingham, Blackburn, Bournemouth, Bradford, Bristol, Bromborough, Chichester, Cosham
2025-07-22
Recruiting
AstraZeneca
Phase 2
100
Bristol, Dundee, Headington, London, Norwich
2025-07-17
Recruiting
Eli Lilly and Company
Phase 3
350
Bristol, Dundee, Exeter, London
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Airdrie, Ashington, Belfast, Bournemouth, Bridgend, Bristol, Chichester, Dundee
2025-06-25
Recruiting
Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)
NCT06885931Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
Amber Therapeutics Ltd
Not applicable
86
Bristol, London
2025-06-24
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Bristol
2025-06-19
Recruiting
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland
2025-06-09
Recruiting
AstraZeneca
Phase 3
15,100
Birmingham, Bournemouth, Bridgend, Bristol, Calow, Cambridge, Cardiff, Chippenham
2025-06-04
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Cottingham, Bristol, Cardiff, Coventry, Dundee, Glasgow, London, Manchester
2025-05-22
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Bristol, Clydebank, Exeter, Halifax, Harrow, London
2025-05-20
Recruiting
Hoffmann-La Roche
Phase 3
425
Bristol, Bury, Llanrhystud, London, Stockport
2025-05-12
Recruiting
BioNTech SE
Phase 1/2
594
Bristol, Leeds, Liverpool, London, Manchester, Preston
2025-05-02
Recruiting
AstraZeneca
Phase 1/2
150
Bristol
2025-04-21
Recruiting
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Bristol, Aylesbury, Exeter, Plymouth, Middlesbrough, Lincoln, London, Oxford
2025-04-11
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
Basildon, Bristol, Leeds, Leicester, London
2025-04-04
Recruiting
Eli Lilly and Company
Phase 2
200
Birmingham, Blackpool, Bristol, Bromborough, Newcastle, Newquay, Nuneaton, Poole
2025-03-28
Recruiting
AstraZeneca
Phase 3
400
Belfast, Birmingham, Bradford, Bristol, Chorley, Leeds, Liverpool, Nottingham
2025-03-28
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Leeds, Bristol, Cardiff, London, Southampton
2025-03-20
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Plymouth, Hampstead, Bristol, Cambridge, Frimley, London
2025-03-20
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Bristol, Glasgow, Salford, Southampton
2025-03-18
Active, closed
Amgen
Phase 3
1,105
Belfast, Birmingham, Blackpool, Bristol, Ely, Glasgow, Hull, Leicester
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Belfast, Birmingham, Blackpool, Bristol, Cornwall, Ely, Glasgow, Hull
2025-03-12
Recruiting
Pfizer
Phase 3
723
Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield
2025-03-11
Recruiting
UCB Biopharma SRL
Phase 3
40
Bristol, Manchester, Nottingham, Stoke-on-Trent
2025-03-11
Recruiting
Inari VISION Registry
NCT06600542Pulmonary Embolism
Inari Medical
Observational
1,000
Bristol, Glasgow, London, Newcastle, Swindon
2025-03-07
Recruiting
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Recruiting
Tensi+ European Registry
NCT07205445Overactive Bladder
Stimuli Technology
Observational
500
Bristol, Cambridge, London
2025-02-27
Active, closed
Novo Nordisk A/S
Phase 3
400
Bristol, Cambridge, Coventry, Liverpool, London, Swansea, Taunton
2025-02-10
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Bristol, Cambridge, London, Newcastle
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth
2025-02-01
Recruiting
Incyte Corporation
Phase 3
240
Bristol, Glasgow, Leeds, London, Manchester, Nottingham, Plymouth
2025-01-21
Recruiting
GE Healthcare
Phase 4
50
Bristol, London
2025-01-20
Recruiting
RevBio
Not applicable
15
Bristol
2025-01-15
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Bristol, Exeter, Newcastle, Norwich, Northamptonshire, Bicester, Oxford, Somerset
2024-12-02
Active, closed
Pharvaris Netherlands B.V.
Phase 3
81
London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth
2024-12-01
Recruiting
Eli Lilly and Company
Phase 3
125
Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool
2024-11-18
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Aberdeen, Bristol, Camberley, Derby, Edgbaston, Birmingham, Exeter, Glasgow, Hull
2024-11-12
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Liverpool, York, Bristol, London, Newcastle upon Tyne
2024-10-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Aberdeen, Ashton in Makerfield, Bristol, Camberley, Dagenham, Edgbaston, Birmingham, Edgware, Enfield, London
2024-10-14
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Basingstoke, Bristol, London
2024-10-09
Recruiting
GlaxoSmithKline
Phase 2
393
Bristol, Cambridge, Glasgow Strathclyde, Leeds West Yorkshire, Liverpool, London, Middlesbrough, Plymouth
2024-09-27
Active, closed
Nocion Therapeutics
Phase 2
455
Belfast, Bristol, Cottingham, London, Wythenshawe, Nottingham, North Shields
2024-09-24
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Bristol, Headington, London, Newcastle upon Tyne
2024-09-19
Active, closed
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Recruiting
AbbVie
Phase 2
590
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
Epsilogen Ltd
Phase 1
45
Bristol, Edinburgh, Leeds, London, Southampton
2024-09-03
Recruiting
Alimera Sciences
Phase 4
25
Bristol, Sheffield
2024-08-31
Active, closed
Boehringer Ingelheim
Phase 3
11,000
Antrim, Basildon, Belfast, Birmingham, Blackburn, Brighton, Bristol, Bury St Edmunds
2024-08-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London
2024-08-30
Active, closed
Kite, A Gilead Company
Phase 3
452
Bristol, Cardiff, Leeds, London, Newcastle
2024-08-23
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
London, York, Bradford, Bristol, Liverpool, Sunderland, Wolverhampton
2024-08-07
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Bebington, Guildford, Aberdeen, Birmingham, Bristol, Cambridge, Glasgow, Liverpool
2024-07-31
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Active, closed
Celldex Therapeutics
Phase 3
976
Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley
2024-07-19
Active, closed
GRIN Therapeutics, Inc.
Phase 1/2
30
Bristol
2024-07-10
Recruiting
AbbVie
Phase 3
40
Sheffield, Bristol, Liverpool
2024-07-08
Active, closed
AbbVie
Phase 3
1,400
Truro, Dunfermline, Gloucester, London, Harrogate, Shoreham-by-Sea, Bristol, Newcastle upon Tyne
2024-06-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Hills Road, Truro, London, Edinburgh, Leeds
2024-06-24
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Barnet, Bristol, Exeter, Halifax, High Wycombe, London, Oldham, Sheffield
2024-06-17
Active, closed
AskBio Inc
Phase 2
127
Bristol, Cardiff
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Bristol, Leicester, London, Sunderland
2024-05-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth
2024-05-24
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Exeter, Bournemouth, Bristol, Edinburgh, London, Sheffield, Swansea
2024-05-20
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Recruiting
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Active, closed
AstraZeneca
Phase 3
2,554
Bristol, Cambridge, Dundee, Glasgow, Harrow, Hounslow, Leicester, Liverpool
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Bristol, Bury, Cambridge, Cardiff, London, North Shields
2024-03-27
Active, closed
Eli Lilly and Company
Phase 3
320
Bristol, Edinburgh, Glasgow, Nuneaton, Preston, Rochdale, Salford, Stevenage
2024-03-15
Recruiting
AstraZeneca
Phase 3
100
Birmingham, Bristol, Liverpool, London, Manchester, Southampton
2024-03-14
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
High Wycombe, Bristol, Glasgow, Hull, London, Oxford, Portsmouth, Preston
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Bristol, Guildford, Coventry, London
2024-03-12
Active, closed
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Active, closed
Sanofi
Phase 3
464
Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool
2024-02-29
Active, closed
Acumen Pharmaceuticals
Phase 2
542
London, Winchester, Motherwell, Preston, Guildford, Sheffield, Bristol
2024-02-29
Recruiting
Hydrolysed Rice Formula Study
NCT06288503Cow's Milk Protein Allergy
Nutricia UK Ltd
Not applicable
86
Gloucester, Bristol
2024-02-01
Active, closed
BicycleTx Limited
Phase 2
375
Bristol, Cambridge, London, Plymouth, Sutton
2024-01-24
Recruiting
Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access
NCT05846581Chronic Kidney Diseases, End Stage Renal Disease on Dialysis
W.L.Gore & Associates
Observational
72
Bristol
2024-01-12
Active, closed
RECORDATI GROUP
Phase 2
93
Bristol, London
2024-01-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Active, closed
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
Active, closed
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Recruiting
PlaqueTec Ltd
Not applicable
300
Bournemouth, Bristol, Cambridge, Norwich
2023-09-14
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry
2023-09-11
Active, closed
my mhealth Ltd
Observational
200
Liskeard, Bristol
2023-09-04
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Recruiting
Lung cAncer Robotic Comparative Study
NCT06038227Lung Cancer
Intuitive Surgical
Observational
600
Bristol, Coventry, London
2023-07-15
Active, closed
Novo Nordisk A/S
Phase 3
212
Birmingham, Bristol, Leeds, Liverpool, Southampton
2023-07-07
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
Active, closed
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Recruiting
European Aortic Data Collection Project
NCT05896397Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Chronic Aortic Dissection
Cook Research Incorporated
Observational
600
Birmingham, Bristol, London
2023-05-31
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Bristol, Clydebank, Dorchester, Exeter, High Wycombe, Lincoln, London, Sheffield
2023-04-11
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Bristol, Oxford, Southampton
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
East Sussex, Bristol, London, Crumpsall
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Bristol, London, Manchester
2023-03-08
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Blackpool, Birmingham, Chichester, Bradford, Bradford on Avon, Bristol, Chester, Coventry
2023-03-01
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Bristol, Birmingham, Liverpool, London, Cardiff, Reading
2023-02-17
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Active, closed
Amgen
Phase 3
7,297
Belfast, Birmingham, Blackpool, Bradford, Bristol, Chichester, Chippenham, Craigavon
2022-12-14
Recruiting
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Belfast, Bradford, Bristol, Chelmsford, Corby, Coventry, Hayle, Hull
2022-12-05
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Bristol, Bedford, Torquay, Hull, Colchester, Gloucester, London, Maidstone
2022-11-21
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool
2022-11-08
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Orpington, Blackpool, Bristol, Cambridge, Chester, Chippenham, Coventry, Liverpool
2022-11-01
Active, closed
Berotralstat Treatment in Children With Hereditary Angioedema
NCT05453968Hereditary Angioedema, Pediatric
DrugBerotralstat
BioCryst Pharmaceuticals
Phase 3
29
Bristol
2022-10-25
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Active, closed
Eli Lilly and Company
Phase 3
15,374
Blackburn, Bristol, Coventry, Dundee, Ely, Fowey, Hull, Ipswich
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Recruiting
Pfizer
Phase 2/3
389
Bristol, London
2022-09-22
Active, closed
The Euro-CRAFT Registry
NCT05805462Coronary Microvascular Disease
CoreAalst BV
Observational
671
Bath, Bristol, Essex, Glasgow, London, Oxford
2022-09-22
Active, closed
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Recruiting
Smith & Nephew, Inc.
Not applicable
234
Chertsey, Bath, Bristol, Salford
2022-08-30
Active, closed
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Active, closed
Sanofi
Phase 2/3
1,856
Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool
2022-08-22
Active, closed
Dyne Therapeutics
Phase 1/2
86
Liverpool, Newcastle upon Tyne, Leeds, Bristol, London
2022-08-12
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Bristol, Leicester, London, Swansea
2022-07-22
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
154
Birmingham, Bristol, London
2022-07-13
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Active, closed
Childrens Real Food Tolerance Study
NCT05269992Malnutrition, Child
Nutricia UK Ltd
Not applicable
60
Bristol
2022-05-01
Active, closed
Novo Nordisk A/S
Phase 3
153
Birmingham, Bristol, London
2022-03-24
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Bristol, London, Manchester, Sheffield
2022-03-08
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Recruiting
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
Boston Scientific Corporation
Not applicable
500
Guildford, Cardiff, Belfast, Bristol, London, Norwich, Plymouth
2021-12-21
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
300
Birmingham, Bristol, Glasgow, London, Manchester, Sheffield
2021-12-06
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Bristol, Edinburgh, Leeds, London, Peterborough, Sheffield
2021-12-02
Recruiting
Janssen Pharmaceutica N.V., Belgium
Observational
300
Bristol, London, Maidstone, Nottingham, Surrey
2021-11-18
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms
W.L.Gore & Associates
Observational
614
Bristol, Glasgow, London
2021-10-09
Recruiting
Pfizer
Phase 3
893
Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester
2021-10-04
Active, closed
Nutricia UK Ltd
Not applicable
100
Ashford, Bristol, Chippenham, Clevedon, Dumfries, Guildford, Harrow, Honiton
2021-09-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
2,000
East Sussex, Bristol, London, Manchester
2021-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
DrugSparsentan
Travere Therapeutics, Inc.
Phase 2
67
Bristol, Glasgow, Liverpool, London, Manchester
2021-08-12
By invitation
BioCryst Pharmaceuticals
Phase 3
139
Bristol
2021-07-23
Active, closed
Hoffmann-La Roche
Phase 3
451
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2021-07-14
Recruiting
Corcym S.r.l
Observational
2,150
Birmingham, Bristol, London
2021-06-29
Recruiting
GE Healthcare
Phase 1/2
54
Bristol, London
2021-05-20
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester
2021-05-15
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Active, closed
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Bristol, Cardiff, Glasgow, London
2021-03-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Bangor, Belfast, Brighton, Bristol, Great Maze Pond, Grimsby, Hillingdon, Inverness
2020-09-23
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
Prospective and Non-randomized Registry of CardioCel 3D
NCT04175327Intracardiac and Septal Defects, Valve and Anulus Repair, Great Vessel Reconstruction, Peripheral Vessel Reconstruction
LeMaitre Vascular
Observational
200
Bristol, Newcastle
2020-08-28
Active, closed
Saluda Medical Pty Ltd
Observational
70
Basildon, Middlesbrough, Bristol
2020-08-05
Active, closed
Eisai Inc.
Phase 3
1,400
Bristol, Glasgow, London
2020-07-14
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
Autolus Limited
Phase 1/2
153
Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol
2020-06-03
Active, closed
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Active, closed
Advanced Accelerator Applications
Phase 3
226
Bristol, London, Sheffield
2020-01-08
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Liverpool, Bristol, Glasgow, London
2019-11-26
Active, closed
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
Active, closed
Imara, Inc.
Phase 2
30
Bristol, London
2019-05-22
Active, closed
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Recruiting
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Recruiting
Abbott Medical Devices
Observational
2,000
Norwich, Liverpool, Bristol, Leeds
2019-03-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Bristol, Cardiff, London
2018-11-28
Active, closed
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Recruiting
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
Exelixis
Phase 3
837
Bristol, Cambridge, London, Manchester, Belfast
2018-06-10
Active, closed
pharmaand GmbH
Phase 3
1,097
Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds
2018-05-14
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Airdrie, Bristol, Cardiff, London, Oxford
2018-05-03
Active, closed
Bristol-Myers Squibb
Phase 2/3
714
Bristol, Glasgow, Swansea, London, Inverness
2018-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness
2017-09-12
Active, closed
Persona Partial Knee Clinical Outcomes Study
NCT03034811Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures
Zimmer Biomet
Not applicable
757
Bristol, Derby, Harrogate
2017-02-08
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester
2016-12-22
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Blackwood, Bristol, Metropolitan Borough of Wirral, Nottingham
2016-06
Active, closed
UK Infinity, Post-Market Clinical Follow-up Study
NCT03063593Arthritis, Rheumatoid, Post-traumatic Osteoarthritis, Degenerative Arthritis
Stryker Trauma and Extremities
Observational
500
Torquay, Bournemouth, Bothwell, Oswestry, Sheffield, Nottingham, Bristol, Edinburgh
2016-04-29
Recruiting
Boston Scientific Corporation
Observational
300
Bristol, Glasgow, London, Newcastle upon Tyne
2016-03-07
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston
2015-11-19
Active, closed
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Glasgow, Wonford, London, Sutton, Birmingham, Bristol
2014-12-17
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington
2014-10-31
Active, closed
AstraZeneca
Phase 3
1,837
Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh
2014-04-22
Recruiting
Boston Scientific Corporation
Observational
1,500
Bristol, Glasgow, Liverpool, London, Newcastle, Oxford
2014-03-04
Active, closed
Bristol-Myers Squibb
Observational
800
Bristol
2013-01-30
Recruiting
Boston Scientific Corporation
Observational
4,800
Basildon, Bristol, Leeds, London, Middlesbrough, Stanmore
2012-11-19
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Basildon, Bristol, Exeter, Leeds, London, Middlesbrough
2012-04-03
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Barnstaple, Birmingham, Blackpool, Bristol, Chelmsford, Glasgow, Harrow, Leeds
2012-01
Active, closed
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
NCT01385176Heart Failure, Congestive Heart Failure
Boston Scientific Corporation
Not applicable
118
Bristol, Liverpool, London
2011-09-21
Recruiting
Medtronic
Observational
20,000
Birmingham, Blackpool, Bristol, Leeds, Leicester, Liverpool, London, Manchester
1983-01
Rows per page Showing 1–271 of 271
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/bristol

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 271 of those studies with a site in Bristol.

How many clinical trials are recruiting in Bristol?

136 of the 271 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 3 have not yet opened recruitment, 126 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bristol), 271 studies
PhaseStudiesRecruitingShare
Phase 31627259.8%
Phase 2372313.7%
Observational321811.8%
Not applicable1675.9%
Phase 1/21184.1%
Phase 2/3742.6%
Phase 4431.5%
Phase 1210.7%

Most active sponsors

Lead sponsors with the most studies (Bristol)
Lead sponsorStudiesRecruiting
AstraZeneca2415
Eli Lilly and Company1810
Merck Sharp & Dohme LLC177
Boehringer Ingelheim108
Janssen Research & Development, LLC93
Pfizer85
AbbVie73
Hoffmann-La Roche74
Novo Nordisk A/S71
Boston Scientific Corporation64
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.